<?xml version="1.0" encoding="UTF-8" standalone="no"?><document setID="f7b3f443-e83d-4bf2-0e96-023448fed9a8"><labelDrug name="BRILINTA"><Normalization><mmtx cui="C3163571" preferredWord="Brilinta" semType="phsu, nnon"/></Normalization></labelDrug><generic name="Ticagrelor"/><sentence id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.1" text="Drug Label for drug brand BRILINTA, containing Ticagrelor." type="negative"><entity charOffset="47:57" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.1.e.0" text="ticagrelor" type="Biomedical_Entity"><Normalization><mmtx cui="C1999375" phraseText="Ticagrelor." preferredWord="Ticagrelor" semType="phsu, nnon"/><RxNorm RxCui="1116632"/></Normalization></entity><entity charOffset="26:34" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.1.e.1" text="brilinta" type="Biomedical_Entity"><Normalization><mmtx cui="C3163571" phraseText="Drug Label for drug brand BRILINTA," preferredWord="Brilinta" semType="phsu, nnon"/><RxNorm RxCui="1116636"/></Normalization></entity><entity charOffset="0:19" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.1.e.2" text="drug drug" type="Biomedical_Entity"><Normalization><mmtx cui="C0013231" phraseText="Drug Label for drug brand BRILINTA," preferredWord="Drugs, Non-Prescription" semType="phsu"/><RxNorm RxCui="NA"/></Normalization></entity><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.1.e.1" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.1.e.0"/><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.1.e.2" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.1.e.0"/><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.1.e.2" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.1.e.1"/></sentence><sentence id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.3" text="&lt;item&gt;BRILINTA, like other antiplatelet agents, can cause significant, sometimes fatal bleeding (5.1, 6.1)." type="negative"><entity charOffset="27:46" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.3.e.0" text="antiplatelet agents" type="Biomedical_Entity"><Normalization><mmtx cui="C0085826" phraseText="like other antiplatelet agents," preferredWord="Antiplatelet Agents" semType="phsu"/><RxNorm RxCui="42539"/></Normalization></entity><entity charOffset="6:14" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.3.e.1" text="brilinta" type="Biomedical_Entity"><Normalization><mmtx cui="C3163571" phraseText="&gt;BRILINTA," preferredWord="Brilinta" semType="phsu, nnon"/><RxNorm RxCui="1116636"/></Normalization></entity><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.3.e.1" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.3.e.0"/></sentence><sentence id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.9" text="Stopping BRILINTA increases the risk of subsequent cardiovascular events (5.5)." type="negative"><entity charOffset="9:17" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.9.e.0" text="brilinta" type="Biomedical_Entity"><Normalization><mmtx cui="C3163571" phraseText="Stopping BRILINTA" preferredWord="Brilinta" semType="phsu, nnon"/><RxNorm RxCui="1116636"/></Normalization></entity><entity charOffset="0:8" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.9.e.1" text="stopping" type="Biomedical_Entity"><Normalization><mmtx cui="C0723457" phraseText="Stopping BRILINTA" preferredWord="Stop brand of fluoride" semType="inch, phsu"/><RxNorm RxCui="220037"/></Normalization></entity><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.9.e.1" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.9.e.0"/></sentence><sentence id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.10" text="&lt;item&gt;BRILINTA, like other antiplatelet agents, can cause significant, sometimes fatal bleeding (5.1, 6.1)." type="negative"><entity charOffset="27:46" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.10.e.0" text="antiplatelet agents" type="Biomedical_Entity"><Normalization><mmtx cui="C0085826" phraseText="like other antiplatelet agents," preferredWord="Antiplatelet Agents" semType="phsu"/><RxNorm RxCui="42539"/></Normalization></entity><entity charOffset="6:14" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.10.e.1" text="brilinta" type="Biomedical_Entity"><Normalization><mmtx cui="C3163571" phraseText="&gt;BRILINTA," preferredWord="Brilinta" semType="phsu, nnon"/><RxNorm RxCui="1116636"/></Normalization></entity><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.10.e.1" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.10.e.0"/></sentence><sentence id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.16" text="Stopping BRILINTA increases the risk of subsequent cardiovascular events (5.5)." type="negative"><entity charOffset="9:17" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.16.e.0" text="brilinta" type="Biomedical_Entity"><Normalization><mmtx cui="C3163571" phraseText="Stopping BRILINTA" preferredWord="Brilinta" semType="phsu, nnon"/><RxNorm RxCui="1116636"/></Normalization></entity><entity charOffset="0:8" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.16.e.1" text="stopping" type="Biomedical_Entity"><Normalization><mmtx cui="C0723457" phraseText="Stopping BRILINTA" preferredWord="Stop brand of fluoride" semType="inch, phsu"/><RxNorm RxCui="220037"/></Normalization></entity><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.16.e.1" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.16.e.0"/></sentence><sentence id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.17" text="&lt;item&gt;WARNING: ASPIRIN DOSE AND BRILINTA EFFECTIVENESS" type="negative"><entity charOffset="32:40" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.17.e.0" text="brilinta" type="Biomedical_Entity"><Normalization><mmtx cui="C3163571" phraseText="BRILINTA EFFECTIVENESS" preferredWord="Brilinta" semType="phsu, nnon"/><RxNorm RxCui="1116636"/></Normalization></entity><entity charOffset="15:22" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.17.e.1" text="aspirin" type="Biomedical_Entity"><Normalization><mmtx cui="C0004057" phraseText="ASPIRIN DOSE" preferredWord="Aspirin" semType="phsu, orch"/><RxNorm RxCui="1191"/></Normalization></entity><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.17.e.1" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.17.e.0"/></sentence><sentence biomedicalEntities="2" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.18" lineNumber="39" text="&lt;item&gt;Maintenance doses of aspirin above 100 mg reduce the effectiveness of BRILINTA and should be avoided. " type="regular"><entity charOffset="27:34" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.18.e.0" text="aspirin" type="Drug"><Normalization><mmtx cui="C0004057" phraseText="&gt;Maintenance doses of aspirin" preferredWord="Aspirin" semType="phsu, orch"/><RxNorm RxCui="1191"/></Normalization></entity><entity charOffset="48:72" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.18.e.1" text="reduce the effectiveness" type="Decrease_Interaction"/><entity charOffset="76:84" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.18.e.3" text="BRILINTA" type="Drug"><Normalization><mmtx cui="C3163571" phraseText="the effectiveness of BRILINTA" preferredWord="Brilinta" semType="phsu, nnon"/><RxNorm RxCui="1116636"/></Normalization></entity><drugInteraction id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.18.ddi.1"><interaction trigger="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.18.e.1"><relations><relation type="hasObject"><entity id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.18.e.3"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.18.e.0"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.18.e.0" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.18.e.3" trigger="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.18.e.1" type="Decrease_Interaction"/></sentence><sentence id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.20" text="WARNING: ASPIRIN DOSE AND BRILINTA EFFECTIVENESS" type="negative"><entity charOffset="26:34" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.20.e.0" text="brilinta" type="Biomedical_Entity"><Normalization><mmtx cui="C3163571" phraseText="BRILINTA EFFECTIVENESS" preferredWord="Brilinta" semType="phsu, nnon"/><RxNorm RxCui="1116636"/></Normalization></entity><entity charOffset="9:16" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.20.e.1" text="aspirin" type="Biomedical_Entity"><Normalization><mmtx cui="C0004057" phraseText="ASPIRIN DOSE" preferredWord="Aspirin" semType="phsu, orch"/><RxNorm RxCui="1191"/></Normalization></entity><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.20.e.1" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.20.e.0"/></sentence><sentence id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.34" text="BRILINTA is contraindicated in patients with hypersensitivity (e.g. angioedema) to ticagrelor or any component of the product see Adverse Reactions (6.2)." type="negative"><entity charOffset="0:8" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.34.e.0" text="brilinta" type="Biomedical_Entity"><Normalization><mmtx cui="C3163571" phraseText="BRILINTA" preferredWord="Brilinta" semType="phsu, nnon"/><RxNorm RxCui="1116636"/></Normalization></entity><entity charOffset="83:93" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.34.e.1" text="ticagrelor" type="Biomedical_Entity"><Normalization><mmtx cui="C1999375" phraseText="to ticagrelor" preferredWord="Ticagrelor" semType="phsu, nnon"/><RxNorm RxCui="1116632"/></Normalization></entity><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.34.e.0" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.34.e.1"/></sentence><sentence id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.36" text="&lt;item&gt;Like other antiplatelet agents, BRILINTA increases the risk of bleeding. " type="negative"><entity charOffset="17:36" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.36.e.0" text="antiplatelet agents" type="Biomedical_Entity"><Normalization><mmtx cui="C0085826" phraseText="Like other antiplatelet agents," preferredWord="Antiplatelet Agents" semType="phsu"/><RxNorm RxCui="42539"/></Normalization></entity><entity charOffset="38:46" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.36.e.1" text="brilinta" type="Biomedical_Entity"><Normalization><mmtx cui="C3163571" phraseText="BRILINTA" preferredWord="Brilinta" semType="phsu, nnon"/><RxNorm RxCui="1116636"/></Normalization></entity><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.36.e.0" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.36.e.1"/></sentence><sentence biomedicalEntities="2" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.38" lineNumber="87" text="&lt;item&gt;In PLATO, use of BRILINTA with maintenance doses of aspirin above 100 mg decreased the effectiveness of BRILINTA. " type="regular"><entity charOffset="58:65" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.38.e.0" text="aspirin" type="Drug"><Normalization><mmtx cui="C0004057" phraseText="of aspirin" preferredWord="Aspirin" semType="phsu, orch"/><RxNorm RxCui="1191"/></Normalization></entity><entity charOffset="79:106" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.38.e.1" text="decreased the effectiveness" type="Decrease_Interaction"/><entity charOffset="110:118" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.38.e.3" text="BRILINTA" type="Drug"><Normalization><mmtx cui="C3163571" phraseText="the effectiveness of BRILINTA." preferredWord="Brilinta" semType="phsu, nnon"/><RxNorm RxCui="1116636"/></Normalization></entity><drugInteraction id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.38.ddi.1"><interaction trigger="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.38.e.1"><relations><relation type="hasPrecipitant"><entity id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.38.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.38.e.3"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.38.e.0" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.38.e.3" trigger="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.38.e.1" type="Decrease_Interaction"/></sentence><sentence id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.42" text="&lt;item&gt;Dyspnea: Dyspnea was reported more frequently with BRILINTA than with clopidogrel. " type="negative"><entity charOffset="76:87" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.42.e.0" text="clopidogrel" type="Biomedical_Entity"><Normalization><mmtx cui="C0070166" phraseText="with clopidogrel." preferredWord="clopidogrel" semType="phsu, orch"/><RxNorm RxCui="236991"/></Normalization></entity><entity charOffset="57:65" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.42.e.1" text="brilinta" type="Biomedical_Entity"><Normalization><mmtx cui="C3163571" phraseText="more frequently with BRILINTA" preferredWord="Brilinta" semType="phsu, nnon"/><RxNorm RxCui="1116636"/></Normalization></entity><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.42.e.1" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.42.e.0"/></sentence><sentence id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.50" text="BRILINTA increased the overall risk of bleeding (Major + Minor) to a somewhat greater extent than did clopidogrel. " type="negative"><entity charOffset="102:113" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.50.e.0" text="clopidogrel" type="Biomedical_Entity"><Normalization><mmtx cui="C0070166" phraseText="clopidogrel." preferredWord="clopidogrel" semType="phsu, orch"/><RxNorm RxCui="236991"/></Normalization></entity><entity charOffset="0:8" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.50.e.1" text="brilinta" type="Biomedical_Entity"><Normalization><mmtx cui="C3163571" phraseText="BRILINTA" preferredWord="Brilinta" semType="phsu, nnon"/><RxNorm RxCui="1116636"/></Normalization></entity><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.50.e.1" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.50.e.0"/></sentence><sentence biomedicalEntities="5" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.53" lineNumber="101" text="In general, risk factors for bleeding include older age, a history of bleeding disorders, performance of percutaneous invasive procedures, and concomitant use of medications that increase the risk of bleeding (e.g., anticoagulant and fibrinolytic therapy, higher doses of aspirin, and chronic nonsteroidal anti-inflammatory drugs NSAIDS )." type="irregular"><entity charOffset="29:37" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.53.e.0" text="bleeding" type="Specific_Interaction"/><entity charOffset="162:208" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.53.e.2" text="medications that increase the risk of bleeding" type="Drug_Class"><Normalization><mmtx cui="C0013227" phraseText="concomitant use of medications" preferredWord="Pharmaceutical Preparations" semType="phsu"/><RxNorm RxCui="691673"/></Normalization></entity><entity charOffset="216:229|247:254" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.53.e.3" text="anticoagulant therapy" type="Drug_Class"><Normalization><mmtx cui="C0003280" phraseText="anticoagulant" preferredWord="Anticoagulants" semType="phsu"/><mmtx cui="C3536711" phraseText="anticoagulant" preferredWord="Anti-coagulant [EPC]" semType="phsu"/><RxNorm RxCui="923"/></Normalization></entity><entity charOffset="234:254" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.53.e.4" text="fibrinolytic therapy" type="Drug_Class"><Normalization><RxNorm RxCui="934"/></Normalization></entity><entity charOffset="272:279" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.53.e.5" text="aspirin" type="Drug"><Normalization><mmtx cui="C0004057" phraseText="higher doses of aspirin," preferredWord="Aspirin" semType="phsu, orch"/><RxNorm RxCui="1191"/></Normalization></entity><entity charOffset="285:336" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.53.e.6" text="chronic nonsteroidal anti-inflammatory drugs NSAIDS" type="Drug_Class"><Normalization><mmtx cui="C0003211" phraseText="chronic nonsteroidal anti-inflammatory drugs NSAIDS" preferredWord="Anti-Inflammatory Agents, Non-Steroidal" semType="phsu"/><mmtx cui="C0003211" phraseText="chronic nonsteroidal anti-inflammatory drugs NSAIDS" preferredWord="Anti-Inflammatory Agents, Non-Steroidal" semType="phsu"/><RxNorm RxCui="1026877"/></Normalization></entity><classClassMembership drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.53.e.3"/><classClassMembership drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.53.e.3"/><drugClassMembership drug="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.53.e.5" drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.53.e.2"/><classClassMembership drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.53.e.6"/><drugInteraction id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.53.ddi.1"><interaction trigger="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.53.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.53.e.2"/></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.49" text="Drugs that inhibit platelet function including BRILINTA increase the risk of bleeding. "><entity charOffset="47:55" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.49.e.0" text="BRILINTA" type="Drug"><Normalization><mmtx cui="C3163571" phraseText="BRILINTA" preferredWord="Brilinta" semType="phsu, nnon"/></Normalization></entity></ellipsisSentence><middleSentence id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.50" text="BRILINTA increased the overall risk of bleeding (Major + Minor) to a somewhat greater extent than did clopidogrel. "/><middleSentence id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.51" text="The increase was seen for non-CABG-related bleeding, but not for CABG-related bleeding. "/><middleSentence id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.52" text="Fatal and life-threatening bleeding rates were not increased see Adverse Reactions (6.1)."/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="labelDrug" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.53.e.2"/></sentence><sentence id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.57" text="Stopping BRILINTA increases the risk of subsequent cardiovascular events see Warnings and Precautions (5.5) and Adverse Reactions (6.1)." type="negative"><entity charOffset="0:8" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.57.e.0" text="stopping" type="Biomedical_Entity"><Normalization><mmtx cui="C0723457" phraseText="Stopping BRILINTA" preferredWord="Stop brand of fluoride" semType="inch, phsu"/><RxNorm RxCui="220037"/></Normalization></entity><entity charOffset="9:17" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.57.e.1" text="brilinta" type="Biomedical_Entity"><Normalization><mmtx cui="C3163571" phraseText="Stopping BRILINTA" preferredWord="Brilinta" semType="phsu, nnon"/><RxNorm RxCui="1116636"/></Normalization></entity><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.57.e.0" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.57.e.1"/></sentence><sentence biomedicalEntities="2" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.59" lineNumber="107" text="In PLATO, use of BRILINTA with maintenance doses of aspirin above 100 mg decreased the effectiveness of BRILINTA. " type="regular"><entity charOffset="73:100" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.59.e.0" text="decreased the effectiveness" type="Decrease_Interaction"/><entity charOffset="104:112" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.59.e.2" text="BRILINTA" type="Drug"><Normalization><mmtx cui="C3163571" phraseText="the effectiveness of BRILINTA." preferredWord="Brilinta" semType="phsu, nnon"/><RxNorm RxCui="1116636"/></Normalization></entity><entity charOffset="52:59" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.59.e.3" text="aspirin" type="Drug"><Normalization><mmtx cui="C0004057" phraseText="of aspirin" preferredWord="Aspirin" semType="phsu, orch"/><RxNorm RxCui="1191"/></Normalization></entity><drugInteraction id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.59.ddi.1"><interaction trigger="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.59.e.0"><relations><relation type="hasObject"><entity id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.59.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.59.e.3"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.59.e.3" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.59.e.2" trigger="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.59.e.0" type="Decrease_Interaction"/></sentence><sentence id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.60" text="Therefore, after the initial loading dose of aspirin (usually 325 mg), use BRILINTA with a maintenance dose of aspirin of 75-100 mg see Dosage and Administration (2) and Clinical Studies (14)." type="negative"><entity charOffset="111:131" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.60.e.0" text="aspirin 75 mg" type="Biomedical_Entity"><Normalization><mmtx cui="C0983879" phraseText="use BRILINTA with a maintenance dose of aspirin of 75-100 mg" preferredWord="Aspirin 75 MG" semType="clnd"/><RxNorm RxCui="1191"/></Normalization></entity><entity charOffset="45:52" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.60.e.1" text="aspirin" type="Biomedical_Entity"><Normalization><mmtx cui="C0004057" phraseText="the initial loading dose of aspirin" preferredWord="Aspirin" semType="phsu, orch"/><RxNorm RxCui="1191"/></Normalization></entity><entity charOffset="75:83" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.60.e.2" text="brilinta" type="Biomedical_Entity"><Normalization><mmtx cui="C3163571" phraseText="use BRILINTA with a maintenance dose of aspirin of 75-100 mg" preferredWord="Brilinta" semType="phsu, nnon"/><RxNorm RxCui="1116636"/></Normalization></entity><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.60.e.1" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.60.e.0"/><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.60.e.2" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.60.e.0"/><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.60.e.1" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.60.e.2"/></sentence><sentence id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.65" text="In PLATO, dyspnea was reported in 14% of patients treated with BRILINTA and in 8% of patients taking clopidogrel. " type="negative"><entity charOffset="63:71" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.65.e.0" text="brilinta" type="Biomedical_Entity"><Normalization><mmtx cui="C3163571" phraseText="treated with BRILINTA" preferredWord="Brilinta" semType="phsu, nnon"/><RxNorm RxCui="1116636"/></Normalization></entity><entity charOffset="101:112" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.65.e.1" text="clopidogrel" type="Biomedical_Entity"><Normalization><mmtx cui="C0070166" phraseText="clopidogrel." preferredWord="clopidogrel" semType="phsu, orch"/><RxNorm RxCui="236991"/></Normalization></entity><entity charOffset="3:8" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.65.e.2" text="plato" type="Biomedical_Entity"><Normalization><mmtx cui="C0043566" phraseText="In PLATO," preferredWord="(1,2-diamino-4-nitrobenzene)dichloroplatinum(II)" semType="phsu, orch"/><RxNorm RxCui="NA"/></Normalization></entity><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.65.e.0" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.65.e.1"/><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.65.e.2" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.65.e.0"/><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.65.e.2" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.65.e.1"/></sentence><sentence id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.66" text="Dyspnea was usually mild to moderate in intensity and often resolved during continued treatment, but occasionally required discontinuation (0.9% of patients taking BRILINTA versus 0.1% of patients taking clopidogrel). " type="negative"><entity charOffset="204:215" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.66.e.0" text="clopidogrel" type="Biomedical_Entity"><Normalization><mmtx cui="C0070166" phraseText="clopidogrel" preferredWord="clopidogrel" semType="phsu, orch"/><RxNorm RxCui="236991"/></Normalization></entity><entity charOffset="164:172" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.66.e.1" text="brilinta" type="Biomedical_Entity"><Normalization><mmtx cui="C3163571" phraseText="BRILINTA" preferredWord="Brilinta" semType="phsu, nnon"/><RxNorm RxCui="1116636"/></Normalization></entity><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.66.e.1" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.66.e.0"/></sentence><sentence id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.69" text="In the case of intolerable dyspnea requiring discontinuation of BRILINTA, consider prescribing another antiplatelet agent." type="negative"><entity charOffset="103:121" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.69.e.0" text="antiplatelet agent" type="Biomedical_Entity"><Normalization><mmtx cui="C0085826" phraseText="another antiplatelet agent." preferredWord="Antiplatelet Agents" semType="phsu"/><RxNorm RxCui="42539"/></Normalization></entity><entity charOffset="64:72" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.69.e.1" text="brilinta" type="Biomedical_Entity"><Normalization><mmtx cui="C3163571" phraseText="of BRILINTA," preferredWord="Brilinta" semType="phsu, nnon"/><RxNorm RxCui="1116636"/></Normalization></entity><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.69.e.1" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.69.e.0"/></sentence><sentence biomedicalEntities="12" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79" lineNumber="124" text="Avoid use with strong CYP3A inhibitors, such as atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole see Drug Interactions (7.1) and Clinical Pharmacology (12.3)." type="irregular"><entity charOffset="15:38" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.0" text="strong CYP3A inhibitors" type="Drug_Class"><Normalization><RxNorm RxCui="608507"/></Normalization></entity><entity charOffset="0:5" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.1" text="Avoid" type="Caution_Interaction"/><entity charOffset="48:58" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.3" text="atazanavir" type="Drug"><Normalization><mmtx cui="C1145759" phraseText="such as atazanavir," preferredWord="Atazanavir" semType="phsu, orch"/><RxNorm RxCui="343047"/></Normalization></entity><entity charOffset="60:74" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.4" text="clarithromycin" type="Drug"><Normalization><mmtx cui="C0055856" phraseText="clarithromycin," preferredWord="Clarithromycin" semType="orch, antb"/><RxNorm RxCui="21212"/></Normalization></entity><entity charOffset="76:85" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.5" text="indinavir" type="Drug"><Normalization><mmtx cui="C0376637" phraseText="indinavir," preferredWord="Indinavir" semType="phsu, orch"/><RxNorm RxCui="114289"/></Normalization></entity><entity charOffset="87:99" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.6" text="itraconazole" type="Drug"><Normalization><mmtx cui="C0064113" phraseText="itraconazole," preferredWord="Itraconazole" semType="phsu, orch"/><RxNorm RxCui="28031"/></Normalization></entity><entity charOffset="101:113" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.7" text="ketoconazole" type="Drug"><Normalization><mmtx cui="C0022625" phraseText="ketoconazole," preferredWord="Ketoconazole" semType="phsu, orch"/><RxNorm RxCui="6135"/></Normalization></entity><entity charOffset="115:125" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.8" text="nefazodone" type="Drug"><Normalization><mmtx cui="C0068485" phraseText="nefazodone," preferredWord="nefazodone" semType="phsu, orch"/><RxNorm RxCui="31565"/></Normalization></entity><entity charOffset="127:137" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.9" text="nelfinavir" type="Drug"><Normalization><mmtx cui="C0525005" phraseText="nelfinavir," preferredWord="Nelfinavir" semType="phsu, orch"/><RxNorm RxCui="266565"/></Normalization></entity><entity charOffset="139:148" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.10" text="ritonavir" type="Drug"><Normalization><mmtx cui="C0292818" phraseText="ritonavir," preferredWord="Ritonavir" semType="phsu, orch"/><RxNorm RxCui="85762"/></Normalization></entity><entity charOffset="150:160" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.11" text="saquinavir" type="Drug"><Normalization><mmtx cui="C0286738" phraseText="saquinavir," preferredWord="Saquinavir" semType="phsu, orch"/><RxNorm RxCui="859857"/></Normalization></entity><entity charOffset="162:175" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.12" text="telithromycin" type="Drug"><Normalization><mmtx cui="C0907410" phraseText="telithromycin" preferredWord="telithromycin" semType="orch, antb"/><RxNorm RxCui="274786"/></Normalization></entity><entity charOffset="180:192" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.13" text="voriconazole" type="Drug"><Normalization><mmtx cui="C0393080" phraseText="voriconazole" preferredWord="voriconazole" semType="phsu, orch"/><RxNorm RxCui="121243"/></Normalization></entity><drugClassMembership drug="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.3" drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.0"/><drugClassMembership drug="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.4" drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.0"/><drugClassMembership drug="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.5" drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.0"/><drugClassMembership drug="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.6" drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.0"/><drugClassMembership drug="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.7" drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.0"/><drugClassMembership drug="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.8" drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.0"/><drugClassMembership drug="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.9" drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.0"/><drugClassMembership drug="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.10" drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.0"/><drugClassMembership drug="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.11" drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.0"/><drugClassMembership drug="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.12" drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.0"/><drugClassMembership drug="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.13" drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.0"/><drugInteraction id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.ddi.1"><interaction trigger="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.1"><relations><relation type="hasPrecipitant"><entity id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.0"/></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.78" text="Ticagrelor is metabolized by CYP3A4/5. "><entity charOffset="0:10" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.78.e.0" text="Ticagrelor" type="Drug"><Normalization><mmtx cui="C1999375" phraseText="Ticagrelor" preferredWord="Ticagrelor" semType="phsu, nnon"/></Normalization></entity></ellipsisSentence></relation></relations></interaction></drugInteraction><pair ddi="true" e1="labelDrug" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79.e.0"/></sentence><sentence biomedicalEntities="6" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.81" lineNumber="128" text="Avoid use with potent CYP3A inducers, such as rifampin, dexamethasone, phenytoin, carbamazepine, and phenobarbital see Drug Interactions (7.2) and Clinical Pharmacology (12.3)." type="irregular"><entity charOffset="0:5" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.81.e.0" text="Avoid" type="Caution_Interaction"/><entity charOffset="15:36" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.81.e.2" text="potent CYP3A inducers" type="Drug_Class"><Normalization><RxNorm RxCui="402226"/></Normalization></entity><entity charOffset="46:54" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.81.e.3" text="rifampin" type="Drug"><Normalization><mmtx cui="C0035608" phraseText="such as rifampin," preferredWord="Rifampin" semType="orch, antb"/><RxNorm RxCui="9384"/></Normalization></entity><entity charOffset="56:69" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.81.e.4" text="dexamethasone" type="Drug"><Normalization><mmtx cui="C0011777" phraseText="dexamethasone," preferredWord="Dexamethasone" semType="strd, phsu"/><RxNorm RxCui="22690"/></Normalization></entity><entity charOffset="71:80" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.81.e.5" text="phenytoin" type="Drug"><Normalization><mmtx cui="C0031507" phraseText="phenytoin," preferredWord="Phenytoin" semType="phsu, orch"/><RxNorm RxCui="8183"/></Normalization></entity><entity charOffset="82:95" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.81.e.6" text="carbamazepine" type="Drug"><Normalization><mmtx cui="C0006949" phraseText="carbamazepine," preferredWord="Carbamazepine" semType="phsu, orch"/><RxNorm RxCui="2002"/></Normalization></entity><entity charOffset="101:114" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.81.e.7" text="phenobarbital" type="Drug"><Normalization><mmtx cui="C0031412" phraseText="phenobarbital" preferredWord="Phenobarbital" semType="phsu, orch"/><RxNorm RxCui="8134"/></Normalization></entity><drugClassMembership drug="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.81.e.3" drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.81.e.2"/><drugClassMembership drug="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.81.e.4" drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.81.e.2"/><drugClassMembership drug="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.81.e.5" drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.81.e.2"/><drugClassMembership drug="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.81.e.6" drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.81.e.2"/><drugClassMembership drug="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.81.e.7" drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.81.e.2"/><drugInteraction id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.81.ddi.1"><interaction trigger="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.81.e.0"><relations><relation type="hasObject"><ellipsisSentence id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.78" text="Ticagrelor is metabolized by CYP3A4/5. "><entity charOffset="0:10" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.78.e.0" text="Ticagrelor" type="Drug"><Normalization><mmtx cui="C1999375" phraseText="Ticagrelor" preferredWord="Ticagrelor" semType="phsu, nnon"/></Normalization></entity></ellipsisSentence><middleSentence id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.79" text="Avoid use with strong CYP3A inhibitors, such as atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole see Drug Interactions (7.1) and Clinical Pharmacology (12.3)."/><middleSentence id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.80" text="5.7 Cytochrome CYP3A Potent Inducers"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.81.e.2"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="labelDrug" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.81.e.2"/></sentence><sentence biomedicalEntities="2" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.85" lineNumber="137" text="&lt;item&gt;Avoid use with strong CYP3A inhibitors or CYP3A inducers. " type="irregular"><entity charOffset="6:11" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.85.e.0" text="Avoid" type="Caution_Interaction"/><entity charOffset="21:44" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.85.e.2" text="strong CYP3A inhibitors" type="Drug_Class"><Normalization><RxNorm RxCui="608507"/></Normalization></entity><entity charOffset="48:62" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.85.e.3" text="CYP3A inducers" type="Drug_Class"><Normalization><RxNorm RxCui="24348"/></Normalization></entity><drugInteraction id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.85.ddi.1"><interaction trigger="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.85.e.0"><relations><relation type="hasObject"><ellipsisSentence id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.84" text="Ticagrelor is predominantly metabolized by CYP3A4 and to a lesser extent by CYP3A5."><entity charOffset="0:10" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.84.e.0" text="Ticagrelor" type="Drug"><Normalization><mmtx cui="C1999375" phraseText="Ticagrelor" preferredWord="Ticagrelor" semType="phsu, nnon"/></Normalization></entity></ellipsisSentence></relation><relation type="hasPrecipitant"><entity id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.85.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.85.e.3"/></relation></relations></interaction></drugInteraction><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.85.e.2" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.85.e.3"/><pair ddi="true" e1="labelDrug" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.85.e.2"/><pair ddi="true" e1="labelDrug" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.85.e.3"/></sentence><sentence biomedicalEntities="2" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.87" lineNumber="139" text="&lt;item&gt;Patients receiving more than 40 mg per day of simvastatin or lovastatin may be at increased risk of statin-related adverse effects. " type="irregular"><entity charOffset="52:63" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.87.e.0" text="simvastatin" type="Drug"><Normalization><mmtx cui="C0074554" phraseText="of simvastatin" preferredWord="Simvastatin" semType="phsu, orch"/><RxNorm RxCui="36567"/></Normalization></entity><entity charOffset="67:77" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.87.e.1" text="lovastatin" type="Drug"><Normalization><mmtx cui="C0024027" phraseText="lovastatin" preferredWord="Lovastatin" semType="phsu, orch"/><RxNorm RxCui="6472"/></Normalization></entity><entity charOffset="106:136" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.87.e.2" text="statin-related adverse effects" type="Specific_Interaction"/><drugInteraction id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.87.ddi.1"><interaction trigger="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.87.e.2"><relations><relation type="hasObject"><ellipsisSentence id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.84" text="Ticagrelor is predominantly metabolized by CYP3A4 and to a lesser extent by CYP3A5."><entity charOffset="0:10" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.84.e.0" text="Ticagrelor" type="Drug"><Normalization><mmtx cui="C1999375" phraseText="Ticagrelor" preferredWord="Ticagrelor" semType="phsu, nnon"/></Normalization></entity></ellipsisSentence><middleSentence id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.85" text="&lt;item&gt;Avoid use with strong CYP3A inhibitors or CYP3A inducers. "/><middleSentence id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.86" text="(7.1, 7.2)"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.87.e.1"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.87.e.0"/></relation></relations></interaction></drugInteraction><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.87.e.0" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.87.e.1"/><pair ddi="true" e1="labelDrug" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.87.e.1"/><pair ddi="true" e1="labelDrug" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.87.e.0"/></sentence><sentence biomedicalEntities="2" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.89" lineNumber="141" text="&lt;item&gt;Monitor digoxin levels with initiation of or any change in BRILINTA. " type="regular"><entity charOffset="6:13" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.89.e.0" text="Monitor" type="Caution_Interaction"/><entity charOffset="14:21" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.89.e.2" text="digoxin" type="Drug"><Normalization><mmtx cui="C0012265" phraseText="&gt;Monitor digoxin levels with initiation of" preferredWord="Digoxin" semType="strd, phsu, carb"/><RxNorm RxCui="3407"/></Normalization></entity><entity charOffset="65:73" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.89.e.3" text="BRILINTA" type="Drug"><Normalization><mmtx cui="C3163571" phraseText="change in BRILINTA." preferredWord="Brilinta" semType="phsu, nnon"/><RxNorm RxCui="1116636"/></Normalization></entity><drugInteraction id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.89.ddi.1"><interaction trigger="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.89.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.89.e.3"/></relation><relation type="hasObject"><entity id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.89.e.2"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.89.e.2" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.89.e.3" trigger="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.89.e.0" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="12" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92" lineNumber="148" text="Avoid use of strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin) see Warnings and Precautions (5.6) and Clinical Pharmacology (12.3)." type="irregular"><entity charOffset="0:9" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.e.0" text="Avoid use" type="Caution_Interaction"/><entity charOffset="13:39" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.e.2" text="strong inhibitors of CYP3A" type="Drug_Class"><Normalization><RxNorm RxCui="608507"/></Normalization></entity><entity charOffset="47:59" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.e.3" text="ketoconazole" type="Drug"><Normalization><mmtx cui="C0022625" phraseText="ketoconazole," preferredWord="Ketoconazole" semType="phsu, orch"/><RxNorm RxCui="6135"/></Normalization></entity><entity charOffset="61:73" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.e.4" text="itraconazole" type="Drug"><Normalization><mmtx cui="C0064113" phraseText="itraconazole," preferredWord="Itraconazole" semType="phsu, orch"/><RxNorm RxCui="28031"/></Normalization></entity><entity charOffset="75:87" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.e.5" text="voriconazole" type="Drug"><Normalization><mmtx cui="C0393080" phraseText="voriconazole," preferredWord="voriconazole" semType="phsu, orch"/><RxNorm RxCui="121243"/></Normalization></entity><entity charOffset="89:103" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.e.6" text="clarithromycin" type="Drug"><Normalization><mmtx cui="C0055856" phraseText="clarithromycin," preferredWord="Clarithromycin" semType="orch, antb"/><RxNorm RxCui="21212"/></Normalization></entity><entity charOffset="105:115" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.e.7" text="nefazodone" type="Drug"><Normalization><mmtx cui="C0068485" phraseText="nefazodone," preferredWord="nefazodone" semType="phsu, orch"/><RxNorm RxCui="31565"/></Normalization></entity><entity charOffset="117:126" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.e.8" text="ritonavir" type="Drug"><Normalization><mmtx cui="C0292818" phraseText="ritonavir," preferredWord="Ritonavir" semType="phsu, orch"/><RxNorm RxCui="85762"/></Normalization></entity><entity charOffset="128:138" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.e.9" text="saquinavir" type="Drug"><Normalization><mmtx cui="C0286738" phraseText="saquinavir," preferredWord="Saquinavir" semType="phsu, orch"/><RxNorm RxCui="859857"/></Normalization></entity><entity charOffset="140:150" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.e.10" text="nelfinavir" type="Drug"><Normalization><mmtx cui="C0525005" phraseText="nelfinavir," preferredWord="Nelfinavir" semType="phsu, orch"/><RxNorm RxCui="266565"/></Normalization></entity><entity charOffset="152:161" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.e.11" text="indinavir" type="Drug"><Normalization><mmtx cui="C0376637" phraseText="indinavir," preferredWord="Indinavir" semType="phsu, orch"/><RxNorm RxCui="114289"/></Normalization></entity><entity charOffset="163:173" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.e.16" text="atazanavir" type="Drug"><Normalization><mmtx cui="C1145759" phraseText="atazanavir" preferredWord="Atazanavir" semType="phsu, orch"/><RxNorm RxCui="343047"/></Normalization></entity><entity charOffset="178:191" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.e.17" text="telithromycin" type="Drug"><Normalization><mmtx cui="C0907410" phraseText="telithromycin" preferredWord="telithromycin" semType="orch, antb"/><RxNorm RxCui="274786"/></Normalization></entity><drugClassMembership drug="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.e.3" drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.e.2"/><drugClassMembership drug="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.e.4" drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.e.2"/><drugClassMembership drug="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.e.5" drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.e.2"/><drugClassMembership drug="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.e.6" drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.e.2"/><drugClassMembership drug="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.e.7" drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.e.2"/><drugClassMembership drug="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.e.8" drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.e.2"/><drugClassMembership drug="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.e.9" drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.e.2"/><drugClassMembership drug="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.e.10" drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.e.2"/><drugClassMembership drug="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.e.11" drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.e.2"/><drugClassMembership drug="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.e.16" drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.e.2"/><drugClassMembership drug="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.e.17" drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.e.2"/><drugInteraction id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.ddi.1"><interaction trigger="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.e.0"><relations><relation type="hasPrecipitant"><ellipsisSentence id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.89" text="&lt;item&gt;Monitor digoxin levels with initiation of or any change in BRILINTA. "><entity id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.89.e.3"/></ellipsisSentence><middleSentence id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.90" text="(7.4)"/><middleSentence id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.91" text="7.1 CYP3A inhibitors"/></relation><relation type="hasObject"><entity id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.92.e.2"/></relation></relations></interaction></drugInteraction></sentence><sentence biomedicalEntities="6" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.94" lineNumber="152" text="Avoid use with potent inducers of CYP3A (e.g., rifampin, dexamethasone, phenytoin, carbamazepine and phenobarbital) see Warnings and Precautions (5.7) and Clinical Pharmacology (12.3)." type="irregular"><entity charOffset="0:9" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.94.e.0" text="Avoid use" type="Caution_Interaction"/><entity charOffset="15:39" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.94.e.2" text="potent inducers of CYP3A" type="Drug_Class"><Normalization><RxNorm RxCui="402226"/></Normalization></entity><entity charOffset="47:55" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.94.e.3" text="rifampin" type="Drug"><Normalization><mmtx cui="C0035608" phraseText="rifampin," preferredWord="Rifampin" semType="orch, antb"/><RxNorm RxCui="9384"/></Normalization></entity><entity charOffset="57:70" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.94.e.4" text="dexamethasone" type="Drug"><Normalization><mmtx cui="C0011777" phraseText="dexamethasone," preferredWord="Dexamethasone" semType="strd, phsu"/><RxNorm RxCui="22690"/></Normalization></entity><entity charOffset="72:81" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.94.e.5" text="phenytoin" type="Drug"><Normalization><mmtx cui="C0031507" phraseText="phenytoin," preferredWord="Phenytoin" semType="phsu, orch"/><RxNorm RxCui="8183"/></Normalization></entity><entity charOffset="83:96" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.94.e.6" text="carbamazepine" type="Drug"><Normalization><mmtx cui="C0006949" phraseText="carbamazepine" preferredWord="Carbamazepine" semType="phsu, orch"/><RxNorm RxCui="2002"/></Normalization></entity><entity charOffset="101:114" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.94.e.7" text="phenobarbital" type="Drug"><Normalization><mmtx cui="C0031412" phraseText="phenobarbital" preferredWord="Phenobarbital" semType="phsu, orch"/><RxNorm RxCui="8134"/></Normalization></entity><drugClassMembership drug="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.94.e.3" drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.94.e.2"/><drugClassMembership drug="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.94.e.4" drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.94.e.2"/><drugClassMembership drug="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.94.e.5" drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.94.e.2"/><drugClassMembership drug="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.94.e.6" drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.94.e.2"/><drugClassMembership drug="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.94.e.7" drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.94.e.2"/><drugInteraction id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.94.ddi.1"><interaction trigger="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.94.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.94.e.2"/></relation><relation type="hasObject"><labelDrug text="BRILINTA"/><normalization><mmtx><preferredWord>Brilinta</preferredWord><phraseText>the effectiveness of BRILINTA</phraseText><cuiCode>C3163571</cuiCode><semType>phsu</semType><semType>nnon</semType></mmtx></normalization></relation></relations></interaction></drugInteraction><pair ddi="true" e1="labelDrug" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.94.e.2"/></sentence><sentence biomedicalEntities="2" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.96" lineNumber="156" text="Use of BRILINTA with aspirin maintenance doses above 100 mg reduced the effectiveness of BRILINTA see Warnings and Precautions (5.2) and Clinical Studies (14)." type="regular"><entity charOffset="21:28" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.96.e.0" text="aspirin" type="Drug"><Normalization><mmtx cui="C0004057" phraseText="with aspirin maintenance doses" preferredWord="Aspirin" semType="phsu, orch"/><RxNorm RxCui="1191"/></Normalization></entity><entity charOffset="60:85" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.96.e.1" text="reduced the effectiveness" type="Decrease_Interaction"/><entity charOffset="89:97" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.96.e.3" text="BRILINTA" type="Drug"><Normalization><mmtx cui="C3163571" phraseText="the effectiveness of BRILINTA" preferredWord="Brilinta" semType="phsu, nnon"/><RxNorm RxCui="1116636"/></Normalization></entity><drugInteraction id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.96.ddi.1"><interaction trigger="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.96.e.1"><relations><relation type="hasPrecipitant"><entity id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.96.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.96.e.3"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.96.e.0" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.96.e.3" trigger="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.96.e.1" type="Decrease_Interaction"/></sentence><sentence id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.98" text="Ticagrelor is an inhibitor of CYP3A4/5 and the P-glycoprotein transporter." type="negative"><entity charOffset="14:38" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.98.e.0" text="an 5" type="Biomedical_Entity"><Normalization><mmtx cui="C0526789" phraseText="an inhibitor of CYP3A4/5" preferredWord="AN(5)" semType="phsu, orch"/><RxNorm RxCui="707263"/></Normalization></entity><entity charOffset="0:10" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.98.e.1" text="ticagrelor" type="Biomedical_Entity"><Normalization><mmtx cui="C1999375" phraseText="Ticagrelor" preferredWord="Ticagrelor" semType="phsu, nnon"/><RxNorm RxCui="1116632"/></Normalization></entity><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.98.e.1" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.98.e.0"/></sentence><sentence id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.99" text="7.4 Simvastatin, lovastatin" type="negative"><entity charOffset="4:15" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.99.e.0" text="simvastatin" type="Biomedical_Entity"><Normalization><mmtx cui="C0074554" phraseText="7.4 Simvastatin," preferredWord="Simvastatin" semType="phsu, orch"/><RxNorm RxCui="36567"/></Normalization></entity><entity charOffset="17:27" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.99.e.1" text="lovastatin" type="Biomedical_Entity"><Normalization><mmtx cui="C0024027" phraseText="lovastatin" preferredWord="Lovastatin" semType="phsu, orch"/><RxNorm RxCui="6472"/></Normalization></entity><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.99.e.0" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.99.e.1"/></sentence><sentence biomedicalEntities="4" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.100" lineNumber="162" text="BRILINTA will result in higher serum concentrations of simvastatin and lovastatin because these drugs are metabolized by CYP3A4. " type="regular"><entity charOffset="24:51" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.100.e.0" text="higher serum concentrations" type="Increase_Interaction"/><entity charOffset="55:66" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.100.e.2" text="simvastatin" type="Drug"><Normalization><mmtx cui="C0074554" phraseText="result in higher serum concentrations of simvastatin" preferredWord="Simvastatin" semType="phsu, orch"/><mmtx cui="C0074554" phraseText="result in higher serum concentrations of simvastatin" preferredWord="Simvastatin" semType="phsu, orch"/><RxNorm RxCui="36567"/></Normalization></entity><entity charOffset="71:81" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.100.e.3" text="lovastatin" type="Drug"><Normalization><mmtx cui="C0024027" phraseText="lovastatin" preferredWord="Lovastatin" semType="phsu, orch"/><RxNorm RxCui="6472"/></Normalization></entity><entity charOffset="0:8" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.100.e.4" text="BRILINTA" type="Drug"><Normalization><mmtx cui="C3163571" phraseText="BRILINTA" preferredWord="Brilinta" semType="phsu, nnon"/><RxNorm RxCui="1116636"/></Normalization></entity><entity charOffset="96:127" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.100.e.5" text="drugs are metabolized by CYP3A4" type="Drug_Class"><Normalization><mmtx cui="C0013227" phraseText="these drugs" preferredWord="Pharmaceutical Preparations" semType="phsu"/><RxNorm RxCui="NA"/></Normalization></entity><drugClassMembership drug="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.100.e.2" drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.100.e.5"/><drugClassMembership drug="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.100.e.3" drugClass="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.100.e.5"/><drugInteraction id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.100.ddi.1"><interaction trigger="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.100.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.100.e.4"/></relation><relation type="hasObject"><entity id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.100.e.3"/></relation><relation type="hasObject"><entity id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.100.e.2"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.100.e.4" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.100.e.3" trigger="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.100.e.0" type="Increase_Interaction"/><pair ddi="true" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.100.e.4" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.100.e.2" trigger="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.100.e.0" type="Increase_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.101" lineNumber="162" text="Avoid simvastatin and lovastatin doses greater than 40 mg see Clinical Pharmacology (12.3)." type="irregular"><entity charOffset="0:5|33:51" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.101.e.0" text="Avoid doses greater than" type="Caution_Interaction"/><entity charOffset="6:17" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.101.e.2" text="simvastatin" type="Drug"><Normalization><mmtx cui="C0074554" phraseText="simvastatin" preferredWord="Simvastatin" semType="phsu, orch"/><RxNorm RxCui="36567"/></Normalization></entity><entity charOffset="22:32" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.101.e.3" text="lovastatin" type="Drug"><Normalization><mmtx cui="C0024027" phraseText="lovastatin doses" preferredWord="Lovastatin" semType="phsu, orch"/><RxNorm RxCui="6472"/></Normalization></entity><drugInteraction id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.101.ddi.1"><interaction trigger="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.101.e.0"><relations><relation type="hasObject"><entity id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.101.e.2"/></relation><relation type="hasPrecipitant"><ellipsisSentence id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.100" text="BRILINTA will result in higher serum concentrations of simvastatin and lovastatin because these drugs are metabolized by CYP3A4. "><entity id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.100.e.4"/></ellipsisSentence></relation><relation type="hasObject"><entity id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.101.e.3"/></relation></relations></interaction></drugInteraction></sentence><sentence biomedicalEntities="2" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.103" lineNumber="166" text="Digoxin: Because of inhibition of the P-glycoprotein transporter, monitor digoxin levels with initiation of or any change in BRILINTA therapy see Clinical Pharmacology (12.3)." type="regular"><entity charOffset="66:73" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.103.e.0" text="monitor" type="Caution_Interaction"/><entity charOffset="74:81" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.103.e.2" text="digoxin" type="Drug"><Normalization><mmtx cui="C0012265" phraseText="monitor digoxin levels with initiation of" preferredWord="Digoxin" semType="strd, phsu, carb"/><RxNorm RxCui="3407"/></Normalization></entity><entity charOffset="125:133" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.103.e.3" text="BRILINTA" type="Drug"><Normalization><mmtx cui="C3163571" phraseText="change in BRILINTA therapy" preferredWord="Brilinta" semType="phsu, nnon"/><RxNorm RxCui="1116636"/></Normalization></entity><drugInteraction id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.103.ddi.1"><interaction trigger="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.103.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.103.e.3"/></relation><relation type="hasObject"><entity id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.103.e.2"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.103.e.2" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.103.e.3" trigger="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.103.e.0" type="Caution_Interaction"/></sentence><sentence id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.105" text="BRILINTA can be administered with unfractionated or low-molecular-weight heparin, GPIIb/IIIa inhibitors, proton pump inhibitors, beta-blockers, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers." type="negative"><entity charOffset="190:219" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.105.e.0" text="angiotensin receptor blockers" type="Biomedical_Entity"><Normalization><mmtx cui="C0815017" phraseText="angiotensin receptor blockers." preferredWord="Angiotensin Receptor Antagonists" semType="phsu"/><RxNorm RxCui="839"/></Normalization></entity><entity charOffset="144:184" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.105.e.1" text="angiotensin converting enzyme inhibitors" type="Biomedical_Entity"><Normalization><mmtx cui="C0003015" phraseText="angiotensin converting enzyme inhibitors," preferredWord="Angiotensin-Converting Enzyme Inhibitors" semType="phsu"/><RxNorm RxCui="839"/></Normalization></entity><entity charOffset="52:80" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.105.e.2" text="low-molecular-weight heparin" type="Biomedical_Entity"><Normalization><mmtx cui="C0019139" phraseText="low-molecular-weight heparin," preferredWord="Heparin, Low-Molecular-Weight" semType="phsu, carb"/><RxNorm RxCui="6463"/></Normalization></entity><entity charOffset="0:8" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.105.e.3" text="brilinta" type="Biomedical_Entity"><Normalization><mmtx cui="C3163571" phraseText="BRILINTA" preferredWord="Brilinta" semType="phsu, nnon"/><RxNorm RxCui="1116636"/></Normalization></entity><entity charOffset="105:127" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.105.e.4" text="proton pump inhibitors" type="Biomedical_Entity"><Normalization><mmtx cui="C0358591" phraseText="proton pump inhibitors," preferredWord="Proton Pump Inhibitors" semType="phsu"/><RxNorm RxCui="8879"/></Normalization></entity><entity charOffset="129:142" id="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.105.e.5" text="beta-blockers" type="Biomedical_Entity"><Normalization><mmtx cui="C0001645" phraseText="beta-blockers," preferredWord="Adrenergic beta-Antagonists" semType="phsu"/><RxNorm RxCui="371"/></Normalization></entity><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.105.e.1" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.105.e.0"/><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.105.e.2" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.105.e.0"/><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.105.e.3" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.105.e.0"/><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.105.e.4" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.105.e.0"/><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.105.e.5" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.105.e.0"/><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.105.e.2" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.105.e.1"/><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.105.e.3" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.105.e.1"/><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.105.e.4" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.105.e.1"/><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.105.e.5" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.105.e.1"/><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.105.e.3" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.105.e.2"/><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.105.e.2" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.105.e.4"/><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.105.e.2" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.105.e.5"/><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.105.e.3" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.105.e.4"/><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.105.e.3" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.105.e.5"/><pair ddi="false" e1="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.105.e.4" e2="Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.105.e.5"/></sentence><positiveExamples number="16"/><negativeExamples number="41"/></document>